Antabio
Labège, FranceWebsite
Antabio is a biopharmaceutical company dedicated to discovering and developing innovative small-molecule antibacterial treatments to address the global crisis of antibiotic resistance.
Loading company information...
Antabio is a biopharmaceutical company dedicated to discovering and developing innovative small-molecule antibacterial treatments to address the global crisis of antibiotic resistance.
Company context
Antabio prompts can include culture, product, and business context from this profile.
Role targeting
Pair this profile with an open role to generate focused behavioral and technical questions.
Answer coaching
Practice responses, get feedback, and refine stories before applying or interviewing.
Antabio is a clinical-stage biopharmaceutical company headquartered in Labège, France, focused on addressing the urgent global health crisis of antimicrobial resistance (AMR). Founded in 2009, the company specializes in the discovery and development of innovative small-molecule 'resistance-breakers.' These novel inhibitors are designed to be co-administered with existing antibiotics, effectively disarming bacterial defense mechanisms and restoring the efficacy of standard-of-care treatments against multidrug-resistant Gram-negative pathogens.
Antabio’s mission is to develop innovative antibacterial therapies to address severe, hard-to-treat infections caused by multidrug-resistant Gram-negative bacteria, with the goal to restore the efficacy of antibiotics and play a leading role in the global fight against antimicrobial resistance.
Founded
2009
Headquarters
Labège, France
Employees
11-50
Industry
Biotechnology
Opportunity to work on high-impact, life-saving medical research
Collaborative environment with experts from major global pharmaceutical firms
High pressure associated with clinical-stage drug development timelines
Limited size compared to large multinational pharmaceutical corporations
Funding
Over $60 million
CEO
Marc Lemonnier